Overall market sentiment has been neutral on Sarepta Therapeutics Inc (SRPT) stock lately. SRPT receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With SRPT Stock Today?
Sarepta Therapeutics Inc (SRPT) stock is up 3.14% while the S&P 500 is down -1.5% as of 12:11 PM on Wednesday, May 12. SRPT is higher by $2.23 from the previous closing price of $71.02 on volume of 616,969 shares. Over the past year the S&P 500 is higher by 39.57% while SRPT is down -46.07%. SRPT lost -$8.94 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Sarepta Therapeutics Inc click here.
More About Sarepta Therapeutics Inc
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Click Here to get the full Stock Score Report on Sarepta Therapeutics Inc (SRPT) Stock.
